

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/580,008-Conf. #7744
				Filing Date	May 4, 2007
				First Named Inventor	Axel Unterbeck
				Art Unit	1616
				Examiner Name	A. Soroush
Sheet	1	of	2	Attorney Docket Number	
				04540/1208852-US3	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	Date Considered	
-----------------------	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/580,008-Conf. #7744
				Filing Date	May 4, 2007
				First Named Inventor	Axel Unterbeck
				Art Unit	1616
				Examiner Name	A. Soroush
Sheet	2	of	2	Attorney Docket Number	04540/1208852-US3

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	LU, WEIHUA, et al., "Improving Effect of Huperzine A on Discrimination Performance in Aged Rats and Adult Rats with Experimental Cognitive Impairment", Chemical Abstract + Indexes, American Chemical Society, February 29, 1988, Vol. 108, No. 9, Columbus, US			
	CB	BEJAR, C. et al.: "Effect of Rivastigmine on Scopolamine-Induced Memory Impairment in Rats", European Journal of Pharmacology, January 1, 1999, Vol. 383, No. 3, pp. 231-240, Amsterdam, NL			
	CC	SVESTKA, J., "Nova Psychofarmaka: Kognitivum Rivastigmin. New Psychotropics: Cognitive Enhancer Rivastigmine", Psychiatrie, January 1, 1999, Vol. 3, No. 2, pp. 110-118, Tigis, Prague, CS			
	CD	SHIGETA, M., et al., "Donepezil for Alzheimer's Disease: Pharmacodynamic, Pharmacokinetic, and Clinical Profiles", CNS Drug Reviews, December 21, 2001, Vol. 7, No. 4, pp. 353-368, Branford, CT, US			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.